Daiichi Sankyo clinical trial pipeline

13 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 7 with minor changes only.

1. Notable

   DS-3939a · Advanced Solid Tumors

   Primary completion pushed from Oct 20, 2026 to Aug 11, 2028

   Also in this update: Study completion pushed from Feb 15, 2027 to Nov 11, 2028; and 1 more change in the last 30 days

   Daiichi Sankyo·Phase 1/2· NCT05875168· Registry history of NCT05875168 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   I-DXd in Combination With Atezolizumab With or Without Carboplatin…I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance · Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

   Primary completion pushed from Sep 30, 2026 to Jul 20, 2027

   Also in this update: Study completion pushed from Dec 30, 2026 to Feb 20, 2028

   Daiichi Sankyo·Phase 1/2· NCT06362252· Registry history of NCT06362252 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

3. Notable

   Raludotatug Deruxtecan · Advanced/Metastatic Solid Tumors…Raludotatug Deruxtecan · Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

   Primary and study completion pushed from Sep 30, 2027 to Dec 30, 2029

   Also in this update: Enrollment increased: 200 → 335 participants

   Daiichi Sankyo·Phase 2· NCT06660654· Registry history of NCT06660654 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

4. Notable

   DS-1103a Combination Therapy · Advanced Solid Tumors

   Primary endpoint(s) modified

   Also in this update: Enrollment increased: 108 → 128 participants; Primary completion moved earlier from May 15, 2030 to May 31, 2029

   Daiichi Sankyo·Phase 1· NCT05765851· Registry history of NCT05765851 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

5. Notable

   DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus…DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

   Recruitment opened

   Also in this update: Trial sites expanded: 0 → 5 locations

   Daiichi Sankyo·Phase 3· NCT07683754· Registry history of NCT07683754 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

6. Notable

   Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab…Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) · HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

   Recruitment opened

   Also in this update: Trial sites expanded: 0 → 72 locations

   Daiichi Sankyo·Phase 1/2· NCT07701941· Registry history of NCT07701941 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.